5th European Antibody Congress 2009

References

• Beck A, Hanala S, Reichert JM. 4th European Antibody Congress 2008: December 1–3, 2008, Geneva, Switzerland. MAbs 2009; 1:93 - 103
   PubMedGoogle Scholar
• Beck A, Wurch T, Corvaïa N. Editorial: Therapeutic Antibodies and derivatives: from the bench to the clinic. Curr Pharma Biotechnol 2008; 9:421 - 422
   PubMed Web of Science ®Google Scholar
• Reichert JM. Monoclonal antibodies as innovative therapeutics. Curr Pharm Biotechnol 2008; 9:423 - 430
   PubMed Web of Science ®Google Scholar
• Ruuls SR, Lammerts van Bueren JJ, van de Winkel JG, Parren PW. Novel human antibody therapeutics: the age of the Umabs. Biotechnol J 2008; 3:1157 - 1171
   PubMedGoogle Scholar
• Beck A, Wagner-Rousset E, Wurch T, Corvaia N. Therapeutic antibodies and related products: choosing the right structure for success. Med Sci 2009; 25:1024 - 1032
   Google Scholar
• Bourne T, Fossati G, Nesbitt A. A PEGylated Fab’ fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. Bio Drugs 2008; 22:331 - 337
   Google Scholar
• Strohl WR. Optimization of Fc-mediated effector functions of monoclonal antibodies. Curr Opin Biotechnol 2009; 20:685 - 691
   PubMed Web of Science ®Google Scholar
• Beck A, Iyer H, Reichert JM. European Medicines Agency workshop on biosimilar monoclonal antibodies Meeting Report (London, UK, July 2, 2009). MAbs 2009; 1:394 - 416
   PubMedGoogle Scholar
• Lanthier M, Behrman R, Nardinelli C. Economic issues with follow-on protein products. Nat Rev Drug Discov 2008; 7:733 - 737
   PubMed Web of Science ®Google Scholar
• Schneider CK, Kalinke U. Toward biosimilar monoclonal antibodies. Nat Biotechnol 2008; 26:985 - 990
   PubMed Web of Science ®Google Scholar
• Wang YM, Chow AT. Development of biosimilars-pharmacokinetic and pharmacodynamic considerations. J Biopharm Stat 2010; 20:46 - 61
   PubMed Web of Science ®Google Scholar
• McCabe KW. Guardians at the gate: patent protection for therapeutic monoclonal antibodies—part 1. MAbs 2009; 1:382 - 384
   PubMed Web of Science ®Google Scholar
• Holliday L. Patenting antibodies in Europe. MAbs 2009; 1:385 - 386
   PubMed Web of Science ®Google Scholar
• Hughes B. Gearing up for follow-on biologics. Nat Rev Drug Discov 2009; 8:181
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, et al. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113:3716 - 3725
   PubMed Web of Science ®Google Scholar
• Reichert JM. Antibodies to watch in 2010. MAbs 2010; 2:84 - 100
   PubMed Web of Science ®Google Scholar
• Dillon TM, Ricci MS, Vezina C, Flynn GC, Liu YD, Rehder DS, et al. Structural and functional characterization of disulfide isoforms of the human IgG2 subclass. J Biol Chem 2008; 283:16206 - 16215
   PubMed Web of Science ®Google Scholar
• Wypych J, Li M, Guo A, Zhang Z, Martinez T, Allen MJ, et al. Human IgG2 antibodies display disulfidemediated structural isoforms. J Biol Chem 2008; 283:16194 - 16205
   PubMed Web of Science ®Google Scholar
• Chen X, Liu YD, Flynn GC. The effect of Fc glycan forms on human IgG2 antibody clearance in humans. Glycobiology 2009; 19:240 - 249
   PubMed Web of Science ®Google Scholar
• van der Neut KM, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 2007; 317:1554 - 1557
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Aalberse RC, Schuurman J. When binding is enough: nonactivating antibody formats. Curr Opin Immunol 2008; 20:479 - 485
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Buijsse AO, van den Bremer ET, Verwilligen AY, Bleeker WK, Thorpe SJ, et al. Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol 2009; 27:767 - 771
   PubMed Web of Science ®Google Scholar
• Schneider CK. Monoclonal antibodies—Regulatory challenges. Curr Pharma Biotechnol 2008; 9:431 - 438
   PubMed Web of Science ®Google Scholar
• Atmanène C, Wagner-Rousset E, Malissard M, Chol B, Robert A, Corvaïa N, et al. Extending Mass Spectrometry contribution to therapeutic monoclonal antibody lead selection and development: characterization of antigen/antibody immune complexes using non-covalent ESI-MS. Anal Chem 2009; 81:6364 - 6473
   PubMed Web of Science ®Google Scholar
• Beck A, Bussat MC, Zorn N, Robillard V, Klinguer-Hamour C, Chenu S, et al. Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 819:203 - 218
   PubMed Web of Science ®Google Scholar
• Beck A, Wagner-Rousset E, Bussat MC, Lokteff M, Klinguer-Hamour C, Haeuw JF, et al. Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. Curr Pharma Biotechnol 2008; 9:482 - 501
   PubMed Web of Science ®Google Scholar
• Wagner-Rousset E, Bednarczyk A, Bussat MC, Colas O, Corvaia N, Schaeffer C, et al. The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies. J Chromatogr B Analyt Technol Biomed Life Sci 2008; 872:23 - 37
   PubMed Web of Science ®Google Scholar
• Li H, Sethuraman N, Stadheim TA, Zha D, Prinz B, Ballew N, et al. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat Biotechnol 2006; 24:210 - 215
   PubMed Web of Science ®Google Scholar
• Beck A, Cochet O, Wurch T. GlycoFi’s technology to control the glycosylation of recombinant therapeutic proteins. Expert Op Drug Discov 2010; 5:95 - 111
   PubMed Web of Science ®Google Scholar
• Vlasak J, Ionescu R. Heterogeneity of monoclonal antibodies relvealed by charge-sensitive methods. Curr Pharma Biotechnol 2008; 9:468 - 481
   PubMed Web of Science ®Google Scholar
• Vlasak J, Bussat MC, Wang S, Wagner-Rousset E, Schaefer M, Klinguer-Hamour C, et al. Identification and characterization of asparagine deamidation in the light chain CDR1 of a humanized IgG1 antibody. Anal Biochem 2009; 392:145 - 154
   PubMed Web of Science ®Google Scholar
• Zhou Q, Shankara S, Roy A, Qiu H, Estes S, McVie-Wylie A, et al. Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function. Biotechnol Bioeng 2008; 99:652 - 665
   PubMed Web of Science ®Google Scholar
• Raju TS. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 2008; 20:471 - 478
   PubMed Web of Science ®Google Scholar
• Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109 - 1117
   PubMed Web of Science ®Google Scholar
• Swann PG, Tolnay M, Muthukkumar S, Shapiro MA, Rellahan BL, Clouse KA. Considerations for the development of therapeutic monoclonal antibodies. Curr Opin Immunol 2008; 20:493 - 499
   PubMed Web of Science ®Google Scholar
• Oflazoglu E, Audoly LP. Evolution of anti-CD20 monoclonal antibody therapeutics in oncology. MAbs 2010; 2:14 - 19
   PubMed Web of Science ®Google Scholar
• Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68:3863 - 3872
   PubMed Web of Science ®Google Scholar
• Chartrain M, Chu L. Development and production of commercial therapeutic monoclonal antibodies in mammalian cell expression system: an overview of the current upstream technologies. Curr Pharma Biotechnol 2008; 9:447 - 467
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Damschroder MM, Woods RM, Cook KE, Wu H, Dall’Acqua WF. Structural characterization of a human Fc fragment engineered for extended serum half-life. Mol Immunol 2009; 46:1750 - 1755
   PubMed Web of Science ®Google Scholar
• Bostrom J, Yu SF, Kan D, Appleton BA, Lee CV, Billeci K, et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 2009; 323:1610 - 1614
   PubMed Web of Science ®Google Scholar
• Ezan E, Dubois M, Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009; 134:825 - 834
   PubMed Web of Science ®Google Scholar
• Dubois M, Fenaille F, Clement G, Lechmann M, Tabet JC, Ezan E, et al. Immunopurification and mass spectrometric quantification of the active form of a chimeric therapeutic antibody in human serum. Anal Chem 2008; 80:1737 - 1745
   PubMed Web of Science ®Google Scholar
• Hagman C, Ricke D, Ewert S, Bek S, Falchetto R, Bitsch F. Absolute quantification of monoclonal antibodies in biofluids by liquid chromatography-tandem mass spectrometry. Anal Chem 2008; 80:1290 - 1296
   PubMed Web of Science ®Google Scholar
• Heudi O, Barteau S, Zimmer D, Schmidt J, Bill K, Lehmann N, et al. Towards absolute quantification of therapeutic monoclonal antibody in serum by LC-MS/MS using isotope-labeled antibody standard and protein cleavage isotope dilution mass spectrometry. Anal Chem 2008; 80:4200 - 4207
   PubMed Web of Science ®Google Scholar
• Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009; 27:331 - 337
   PubMed Web of Science ®Google Scholar
• Linke R, Klein A, Seimetz D. Catumaxomab. mAbs 2010; 2
   PubMedGoogle Scholar
• Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today 2005; 10:1451 - 1458
   PubMed Web of Science ®Google Scholar
• Pasut G, Veronese FM. PEGylation for improving the effectiveness of therapeutic biomolecules. Drugs Today 2009; 45:687 - 695
   PubMed Web of Science ®Google Scholar
• Palframan R, Airey M, Moore A, Vugler A, Nesbitt A. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab and infliximab in the inflamed paws of mice with collageninduced arthritis. J Immunol Methods 2009; 348:36 - 41
   PubMed Web of Science ®Google Scholar
• Economides AN, Carpenter LR, Rudge JS, Wong V, Koehler-Stec EM, Hartnett C, et al. Cytokine traps: multi-component, high-affinity blockers of cytokine action. Nat Med 2003; 9:47 - 52
   PubMed Web of Science ®Google Scholar
• McDermott MF. Rilonacept in the treatment of chronic inflammatory disorders. Drugs Today 2009; 45:423 - 430
   PubMed Web of Science ®Google Scholar
• Torres R, Macdonald L, Croll SD, Reinhardt J, Dore A, Stevens S, et al. Hyperalgesia, synovitis and multiple biomarkers of inflammation are suppressed by interleukin 1 inhibition in a novel animal model of gouty arthritis. Ann Rheum Dis 2009; 68:1602 - 1608
   PubMed Web of Science ®Google Scholar
• Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005; 6:1023 - 1032
   Web of Science ®Google Scholar
• Fishwild DM, O’Donnell SL, Bengoechea T, Hudson DV, Harding F, Bernhard SL, et al. High-avidity human IgGkappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14:845 - 851
   PubMed Web of Science ®Google Scholar
• Cingoz Oya. Ustekinumab. MAbs 2009; 1:216 - 221
   PubMed Web of Science ®Google Scholar
• Craigen JL, Mackus WJM, Engleberts P, Miller SR, Speller S, Chamberlain LC, et al. Ofatumumab, a Human Mab Targeting a Membrane-Proximal Small-Loop Epitope On CD20, Induces Potent NK Cell-Mediated ADCC ASH annual meeting 2009 http://ash.confex.com/ash/2009/webprogram/Paper24122.html
   Google Scholar
• de Romeuf C, Dutertre CA, Le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol 2008; 140:635 - 643
   PubMed Web of Science ®Google Scholar
• Beliard R, Waegemans T, Notelet D, Massad L, Dhainaut F, Romeuf C, et al. A human anti-D monoclonal antibody selected for enhanced FcgammaRIII engagement clears RhD+ autologous red cells in human volunteers as efficiently as polyclonal anti-D antibodies. Br J Haematol 2008; 141:109 - 119
   PubMed Web of Science ®Google Scholar
• Jacobs S, Cook S, Svoboda ME, Van Wyk JJ. Interaction of the monoclonal antibodies alpha IR-1 and alpha IR-3 with insulin and somatomedin-C receptors. Endocinol 1986; 118:223 - 226
   PubMed Web of Science ®Google Scholar
• Doern A, Cao X, Sereno A, Reyes CL, Altshuler A, Huang F, et al. Characterization of inhibitory antiinsulin-like growth factor receptor antibodies with different epitope specificity and ligand-blocking properties: implications for mechanism of action in vivo. J Biol Chem 2009; 284:10254 - 10267
   PubMed Web of Science ®Google Scholar
• Rodon J, DeSantos V, Ferry RJ Jr, Kurzrock R. Early drug development of inhibitors of the insulin-like growth factor-I receptor pathway: lessons from the first clinical trials. Mol Cancer Ther 2008; 7:2575 - 2588
   PubMed Web of Science ®Google Scholar
• Allen GW, Saba C, Armstrong EA, Huang SM, Benavente S, Ludwig DL, et al. Insulin-like growth factor-I receptor signaling blockade combined with radiation. Cancer Res 2007; 67:1155 - 1162
   PubMed Web of Science ®Google Scholar
• Deevi D, Burtrum D, Melchior M, Witte L, Ludwig DL, Tonra JR. Efficacy of EGFR and IGF-1R antibody therapy is independent of PTEN status in a selection of tumor models 20th AACR-EORTC-NCI Symposium Oct 21–24 2008 http://91.142.242.133/_stationary/ena2008vol6no12oct2008.pdf
   Google Scholar
• Muller PY, Brennan F. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Thera 2009; 85:247 - 258
   PubMed Web of Science ®Google Scholar
• Ponce R, Abad L, Amaravadi L, Gelzleichter T, Gore E, Green J, et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul Toxicol Pharmacol 2009; 54:164 - 182
   PubMed Web of Science ®Google Scholar
• Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 2009; 20:722 - 729
   PubMed Web of Science ®Google Scholar
• Throsby M, van den Brink E, Jongeneelen M, Poon LL, Alard P, Cornelissen L, et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 2008; 3:3942
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, Friesen RH, Jongeneelen M, Throsby M, et al. Antibody recognition of a highly conserved influenza virus epitope. Science 2009; 324:246 - 251
   PubMed Web of Science ®Google Scholar
• Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity 2006; 24:5 - 9
   PubMed Web of Science ®Google Scholar
• Koudstaal W, Koldijk MH, Brakenhoff JP, Cornelissen LA, Weverling GJ, Friesen RH, et al. Pre- and postexposure use of human monoclonal antibody against H5N1 and H1N1 influenza virus in mice: viable alternative to oseltamivir. J Infect Dis 2009; 200:1870 - 1873
   PubMed Web of Science ®Google Scholar
• Wurch T, Lowe P, Caussanel V, Bes C, Beck A, Corvaia N. Development of novel protein scaffolds as alternatives to whole antibodies for imaging and therapy: status on discovery research and clinical validation. Curr Pharm Biotechnol 2008; 9:502 - 509
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Ginestoux C, Jabado-Michaloud J, Folch G, Bellahcene F, et al. IMGT®, the international ImMunoGeneTics information system®. Nucl Acids Res 2009; 37:1006 - 1012
   PubMed Web of Science ®Google Scholar
• Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, Thullier P. Germline humanization of a nonhuman primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384:1400 - 1407
   PubMed Web of Science ®Google Scholar
• Pelat T, Thullier P. Non-human primate immune libraries combined with germline humanization: an (almost) new, and powerful approach for the isolation of therapeutic antibodies. MAbs 2009; 1:377 - 381
   PubMed Web of Science ®Google Scholar
• Osbourn J, Groves M, Vaughan T. From rodent reagents to human therapeutics using antibody guided selection. Methods 2005; 36:61 - 68
   PubMed Web of Science ®Google Scholar
• Armour KL, van de Winkel JG, Williamson LM, Clark MR. Differential binding to human FcgammaRIIa and FcgammaRIIb receptors by human IgG wildtype and mutant antibodies. Mol Immunol 2003; 40:585 - 593
   PubMed Web of Science ®Google Scholar
• Mersmann M, Meier D, Mersmann J, Helsing S, Nilsson P, Gräslund S, et al. Towards proteome scale antibody selections using phage display. New Biotechnol 2010; In press
   PubMed Web of Science ®Google Scholar
• Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat Biotechnol 2008; 26:925 - 932
   PubMed Web of Science ®Google Scholar
• Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001; 98:2526 - 2534
   PubMed Web of Science ®Google Scholar
• Heiss MM, Ströhlein MA, Jäger M, Kimmig R, Burges A, Schoberth A, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005; 117:435 - 443
   PubMed Web of Science ®Google Scholar
• Koide A, Abbatiello S, Rothgery L, Koide S. Probing protein conformational changes in living cells by using designer binding proteins: application to the estrogen receptor. Proc Natl Acad Sci USA 2002; 99:1253 - 1258
   PubMed Web of Science ®Google Scholar
• Ebersbach H, Fiedler E, Scheuermann T, Fiedler M, Stubbs MT, Reimann C, et al. Affilin-novel binding molecules based on human γ-B-crystallin, an All β-sheet protein. J Mol Biol 2007; 372:172 - 185
   PubMed Web of Science ®Google Scholar
• Grabulovski D, Kaspar M, Neri D. A novel, nonimmunogenic Fyn SH3-derived binding protein with tumor vascular targeting properties. J Biol Chem 2007; 282:3196 - 3204
   PubMed Web of Science ®Google Scholar
• Holt LJ, Herring C, Jespers LS, Woolven BP, Tomlinson IM. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21:484 - 490
   PubMed Web of Science ®Google Scholar
• Revets H, De Baetselier P, Muyldermans S. Nanobodies as novel agents for cancer therapy. Expert Opin Biol Ther 2005; 5:111 - 124
   PubMed Web of Science ®Google Scholar
• Levy JH, O’Donnell PS. The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. Expert Opin Investig Drugs 2006; 15:1077 - 1090
   PubMed Web of Science ®Google Scholar
• Nixon AE, Wood CR. Engineered protein inhibitors of proteases. Curr Opin Drug Discov Devel 2006; 9:261 - 268
   PubMed Web of Science ®Google Scholar
• Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: A clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol 2007; 120:416 - 422
   PubMed Web of Science ®Google Scholar
• Stumpp MT, Amstutz P. DARPins: A true alternative to antibodies. Curr Opin Drug Discov Devel 2007; 10:153 - 159
   PubMed Web of Science ®Google Scholar
• Stumpp MT, Binz HK, Amstutz P. DARPins: A new generation of protein therapeutics. Drug Discov Today 2008; 13:695 - 701
   PubMed Web of Science ®Google Scholar